Executive SummaryApproached creatively, the Web offers biotechs a distribution medium for the selling of expertise as expertise, rather than as therapeutic products, and its application to many problems, not a specific few. Such a strategy is directly contradictory to a biotech model built around exclusive collaborations. But the Web-enabled possibility of selling expertise broadly changes the biotech's customer base. Where biotechs currently look to sell a few, high-cost deals in which most of the funding comes at the end of a highly risky project, the Web-biotech sells to many subscribers who pay up front.
You may also be interested in...
The US Senate’s vote to approve legislation underpinning the US-Mexico-Canada trade agreement has been welcomed by the country’s off-patent industry.
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.